• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Jasper Therapeutics Inc.

    5/19/25 8:02:13 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $JSPR alert in real time by email
    DEFA14A 1 ea0241493-02.htm DEFINITIVE ADDITIONAL MATERIALS

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ________________________________

    SCHEDULE 14A INFORMATION

    ________________________________

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.   )

    Filed by the Registrant

     

    ☒

    Filed by a Party other than the Registrant

     

    ☐

    Check the appropriate box:

    ☐

     

    Preliminary Proxy Statement

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

    Definitive Proxy Statement

    ☒

     

    Definitive Additional Materials

    ☐

     

    Soliciting Material under §240.14a-12

    JASPER THERAPEUTICS, INC.
    (Name of Registrant as Specified In Its Charter)

    N/A
    _____________________________________________________________
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

     

    No fee required.

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

    2025 You May Vote Your Proxy When You View The Material On The Internet. You Will Be Asked To Follow The Prompts To Vote Your Shares. Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City, CA 94065 Jasper Therapeutics, Inc. c/o Continental Proxy Services 1 State Street, New York NY 10004 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS to be held on July 3, 2025 *Stockholders are cordially invited to attend the Annual Meeting and vote in person. At the meeting, you will need to request a ballot to vote your shares. Dear Stockholder, The 2025 Annual Meeting of Stockholders of Jasper Therapeutics, Inc. will be held virtually at https://cstproxy.com/JasperTherapeutics/2025 on Thursday, July 3, 2025, at 10:00 a.m. Pacific Time. Proposals to be considered at the Annual Meeting: (1) Election of three Class I directors to serve until the 2028 annual meeting of stockholders; (2) Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025; (3) Advisory vote on approval of the compensation of the named executive officers; and (4) Advisory vote on the frequency of future advisory votes on executive compensation. The Board of Directors recommends a vote “FOR” all nominees under Proposal 1, “FOR” Proposals 2 and 3 and “ONE YEAR” for Proposal 4. Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned the proxy card. Vote during the Meeting – If you plan to attend the virtual online Annual Meeting, you will need your 12 digit control number to vote electronically during the annual meeting. To attend the annual meeting, visit: https://www.cstproxy.com/JasperTherapeutics/2025 Vote Your Proxy on the Internet: Go to http://www.cstproxyvote.com Have your notice available when you access the above website. Follow the prompts to vote your shares. CONTROL NUMBER The Proxy Materials are available for review at: https://www.cstproxy.com/JasperTherapeutics/2025

     

    2025 Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City, CA 94065 Important Notice Regarding the Availability of Proxy Materials for the 2025 Annual Meeting of Stockholders to be Held On Thursday, July 3, 2025 The following Proxy Materials are available to you to review at: https://www.cstproxy.com/JasperTherapeutics/2025 - the Company’s Annual Report on Form 10-K for the year ended December 31, 2024; - the Company’s 2025 Proxy Statement; - the Proxy Card; and - any amendments to the foregoing materials that are required to be furnished to stockholders. This is not a ballot. You cannot use this notice to vote your shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you would like to receive a paper or e-mail copy of these documents, you must request one. There is no charge for such documents to be mailed to you. Please make your request for a copy as instructed below on or before June 19, 2025 to facilitate a timely delivery. You may also request that you receive paper copies of all future proxy materials from the Company. ACCESSING YOUR PROXY MATERIALS ONLINE Have this notice available when you request a paper copy of the proxy materials or to vote your proxy electronically. You must reference your Control number. REQUESTING A PAPER COPY OF THE PROXY MATERIALS By telephone please call 1-888-266-6791, or By logging on to https://www.cstproxy.com/JasperTherapeutics/2025 or By email at: [email protected] Please include the company name and your control number in the subject line.

     

    Get the next $JSPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JSPR

    DatePrice TargetRatingAnalyst
    1/13/2026$17.00Buy
    Rodman & Renshaw
    7/8/2025$4.00Outperform → Market Perform
    BMO Capital Markets
    7/8/2025$5.00Outperform → Sector Perform
    RBC Capital Mkts
    7/7/2025Overweight → Neutral
    Cantor Fitzgerald
    7/7/2025Outperform → Mkt Perform
    William Blair
    2/13/2025$38.00Buy
    UBS
    12/6/2024$63.00Outperform
    BMO Capital Markets
    9/9/2024$70.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $JSPR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.

    SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

    2/12/26 10:33:02 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.

    SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

    2/11/26 1:38:43 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.

    SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    1/26/26 3:29:02 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

    67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference

    1/8/26 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

    Thomas Wiggans appointed Executive Chairperson  Jasper to host an investor webinar on January 8th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced that its Board of Directors has appointed Jeet Mahal as President and Chief Executive Officer

    1/7/26 4:30:00 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

    Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117)

    12/2/25 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Jasper Therapeutics from Outperform to Market Perform and set a new price target of $4.00

    7/8/25 8:30:26 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Jasper Therapeutics from Outperform to Sector Perform and set a new price target of $5.00

    7/8/25 8:30:05 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Mahal Jeetinder Singh

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    2/10/26 4:00:23 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President, CEO and Director Martell Ron

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    1/5/26 7:30:55 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Operating Officer Mahal Jeetinder Singh

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    1/5/26 7:30:34 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wiggans Thomas G bought $99,630 worth of Voting Common Stock (41,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Lucas Svetlana bought $48,600 worth of Voting Common Stock (20,000 units at $2.43) (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:38 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Martell Ron bought $99,630 worth of Voting Common Stock (41,000 units at $2.43), increasing direct ownership by 124% to 74,118 units (SEC Form 4)

    4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)

    9/24/25 4:01:19 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Financials

    Live finance-specific insights

    View All

    Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

    67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference

    1/8/26 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

    Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117)

    12/2/25 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

    11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell drive

    6/14/25 10:00:23 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Leadership Updates

    Live Leadership Updates

    View All

    Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

    REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B

    6/19/24 8:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

    REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re

    11/1/23 8:00:00 AM ET
    $DERM
    $JSPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Jasper Therapeutics Strengthens Management Team with Key Appointments

    Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations

    8/2/23 8:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $JSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 3:32:57 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/4/24 12:05:53 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care